Guggenheim maintains Beam Therapeutics at Buy, lowers price target to $51 from $55

Guggenheim kept its Buy rating on Beam Therapeutics but reduced its price target to $51 from $55, a 7.3% decrease. The new target suggests an 83.5% upside from the Nov 4 close of $27.79. Recent analyst notes on the company have price targets ranging from $30 to $80.

Original reporting
Published Nov 5, 2026, 4:09 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 5, 2026, 4:16 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Guggenheim maintains Beam Therapeutics at Buy, lowers price target to $51 from $55 — source image
Decision brief

The 30-second read

$BEAMBearishMed
01

Why it matters

The target cut reflects revised expectations for Beam Therapeutics' near‑term performance, likely prompting a modest sell‑off.

02

Market read

Analyst target reduction is a fresh piece of information that can influence trader decisions on BEAM today.

03

What to watch

Potential upcoming clinical data or partnership announcements could offset the target reduction.

Relevance 6/10Novelty 6/10Timing: pre‑market today

Background

Analyst price‑target adjustments are a common catalyst for short‑term price moves in biotech stocks.

Company-level read

Ticker impact

$BEAMBearishHigh confidence
Context

Guggenheim lowered Beam Therapeutics price target to $51 from $55, maintaining a Buy rating.

Expected impact

likely downward pressure as the market prices in the reduced target

Evidence & confidence

Target reduction of ~7% signals weaker expectations, prompting short‑term sell pressure.

Market effects

May temper enthusiasm for the broader gene‑editing biotech sector.

Limited to US biotech investors; no broader regional effect.

Minimal global impact beyond niche biotech investors.

Counterpoint

Despite the target cut, the Buy rating remains, suggesting upside if the market overreacts.

Key entities

  • Guggenheim

    Equity research firm providing the rating and price target.

  • Beam Therapeutics

    US‑listed biotech focused on gene‑editing technologies.

Related articles

$BEAMHighAI 9/10

Beam Sickle Cell Therapy Meets Pivotal Goals

Beam Therapeutics reported positive pivotal trial results for risto-cel, its sickle cell treatment, meeting all primary and secondary endpoints. The trial showed patients stayed free of severe vaso-occlusive crises for at least 12 months. Beam plans to file for FDA approval by year-end 2026, aiming to be the first base-editing therapy approved in the US. The company will present detailed results at a medical meeting in 2027.